THE DEAL, AT A GLANCE
2/4 explanations supportedSling Therapeutics
01Product illustration not yet availableWhat it doesSling develops linsitinib, an oral medicine being tested for thyroid eye disease.Source-grounded · automated review · Explore ↗
Checked 2026-09-16 · Review due 2026-09-23
Read supporting source ↗Our lead pipeline program, linsitinib,…
02Who is involvedEvidence still neededOpen review status ↗
The draft does not name investors and correctly states that the supplied document names no investors, lenders, arrangers, or financing participants for a Series C event.
03What happenedEvidence still neededOpen review status ↗
The supplied document does not establish a Series C financing, financing date, amount, currency, valuation, or completed transaction. eventMatch must be false.
04Why it mattersIts stated goal is convenient treatment for people with thyroid eye disease.Source-grounded · automated review · Explore ↗
Click a part to explore its evidence. Unsupported imagery is withheld rather than guessed.Original record source ↗
Sling Therapeutics · Financing Record
Explore source-linked visual explanations for Sling Therapeutics. Unsupported claims are withheld while source review continues.
Record 12427 · Recorded date: 2026-09-16
Explore company records →